J&J's Erleada Approved By FDA In New Prostate Cancer Indication

Erleada was approved for treatment of metastatic castration-sensitive prostate cancer (mCSPC), strengthening its position versus generic Zytiga and Pfizer/Astellas's Xtandi.

Prostate-cancer
Erleada was approved by FDA for metastatic castration-sensitive prostate cancer

Johnson & Johnson's androgen receptor inhibitor Erleada (apalutamide) was approved by the US Food and Drug Administration for a new indication in patients with metastatic castration-sensitive prostate cancer (mCSPC), the company announced on 17 September, giving it a small lead in the indication over Xtandi (enzalutamide).

Erleada is J&J's newer androgen receptor inhibitor, which the company hopes can fill some of the gap left by the...

More from Anticancer

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.